Search

Your search keyword '"CTI Leusen"' showing total 70 results

Search Constraints

Start Over You searched for: Author "CTI Leusen" Remove constraint Author: "CTI Leusen"
70 results on '"CTI Leusen"'

Search Results

1. Enhancing IgA-mediated neutrophil cytotoxicity against neuroblastoma by CD47 blockade

2. Radiation response assessment of organoids derived from patients with pancreatic cancer

3. MUC13 negatively regulates tight junction proteins and intestinal epithelial barrier integrity via protein kinase C

5. The Effect of Radiation Treatment of Solid Tumors on Neutrophil Infiltration and Function: A Systematic Review

6. Enhancing neutrophil cytotoxicity of a panel of clinical EGFR antibodies by Fc engineering to IgA3.0

7. Leukocyte-associated immunoglobulin-like receptor-1 blockade in combination with programmed death-ligand 1 targeting therapy mediates increased tumour control in mice

9. Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria

10. IgM anti-GM2 antibodies in patients with multifocal motor neuropathy target Schwann cells and are associated with early onset

11. Comprehensive single-cell genome analysis at nucleotide resolution using the PTA Analysis Toolbox

12. Daily intranasal palivizumab to prevent respiratory syncytial virus infection in healthy preterm infants: a phase 1/2b randomized placebo-controlled trial

13. Targeting the myeloid microenvironment in neuroblastoma

15. Sialic Acids on Tumor Cells Modulate IgA Therapy by Neutrophils via Inhibitory Receptors Siglec-7 and Siglec-9

16. Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells

17. IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models

18. Characterization of human Fc alpha receptor transgenic mice: comparison of CD89 expression and antibody-dependent tumor killing between mouse strains

19. Controlled release of enhanced cross-hybrid IgGA Fc PD-L1 inhibitors using oncolytic adenoviruses

20. Effective, Long-Term, Neutrophil Depletion Using a Murinized Anti-Ly-6G 1A8 Antibody

22. Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab

23. IgG Subclass-Dependent Pulmonary Antigen Retention during Acute IgG-Dependent Systemic Anaphylaxis in Mice

24. Fc gamma receptor is not required for in vivo processing of radio- and drug-conjugates of the dead tumor cell-targeting monoclonal antibody, APOMAB (R)

25. MutationalPatterns: the one stop shop for the analysis of mutational processes

26. Analysing the protection from respiratory tract infections and allergic diseases early in life by human milk components: the PRIMA birth cohort

27. Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure

28. Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement

29. Anti-C2 Antibody ARGX-117 Inhibits Complement in a Disease Model for Multifocal Motor Neuropathy

30. Tumor cell lysis and synergistically enhanced antibody-dependent cell-mediated cytotoxicity by NKG2D engagement with a bispecific immunoligand targeting the HER2 antigen

31. Tumor to normal single-cell mRNA comparisons reveal a pan-neuroblastoma cancer cell

32. Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma

33. The selection of variable regions affects effector mechanisms of IgA antibodies against CD20

34. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids

35. Complement receptor 3 mediates both sinking phagocytosis and phagocytic cup formation via distinct mechanisms

36. Synergestic Tumor-Killing Effect by Cross-Hybrid IgGA Fc

37. Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactions

38. Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo

39. ARGX-117, a therapeutic complement inhibiting antibody targeting C2

40. Bivalent binding on cells varies between anti-CD20 antibodies and is dose-dependent

41. IgA-mediated killing of tumor cells by neutrophils is enhanced by CD47–SIRPA checkpoint inhibition

42. Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies

43. Bovine IgG Prevents Experimental Infection With RSV and Facilitates Human T Cell Responses to RSV

44. gamma 9 delta 2T cell diversity and the receptor interface with tumor cells

45. Immune Effector Functions of Human IgG2 Antibodies against EGFR

46. Functional diversification of hybridoma-produced antibodies by CRISPR/HDR genomic engineering

47. CD47 Blockade and Rituximab in Non-Hodgkin’s Lymphoma

48. CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping

49. Prediction of pre-eclampsia: review of reviews

50. Heparin Forms Polymers with Cell-free DNA Which Elongate Under Shear in Flowing Blood

Catalog

Books, media, physical & digital resources